ARGX vs. BMY: argenx vs. Bristol-Myers Squibb Stock Comparison

Company Profile

argenx (ARGX) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while BMY is classified in Pharmaceuticals.

Bristol-Myers Squibb (BMY) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas argenx (ARGX) sees a more moderate 359.84K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Bristol-Myers Squibb (BMY) earns 44.01% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

Both argenx (ARGX) at 31.73% and Bristol-Myers Squibb (BMY) at 18.47% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both argenx (ARGX) at 36.27% and Bristol-Myers Squibb (BMY) at 33.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Bristol-Myers Squibb (BMY) at -0.22% is closer to the peer norm — faster top-line expansion for ARGX.

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Bristol-Myers Squibb (BMY) shows current ratio of 1.59 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Bristol-Myers Squibb (BMY) at 1.91 is above its industry debt-to-equity ratio range.

Financial Strength Metrics

Dividends

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both argenx (ARGX) at 32.12 and Bristol-Myers Squibb (BMY) at 13.78 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bristol-Myers Squibb (BMY) at 5.43 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

Valuation Metrics